{"name":"Bicara Therapeutics","slug":"bicara-therapeutics","ticker":"","exchange":"","domain":"bicara.com","description":"Bicara Therapeutics is a biotechnology company focused on developing innovative therapies for cancer. The company's lead candidate, BCA101, is currently in Phase 1 clinical trials. Despite significant R&D investments, the company has not yet generated revenue and reported a net loss.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":63600000,"netIncome":-137950000,"cash":96685000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxPTF9kWk8tNnZRZ0F0TGVjZ01CZGdKLTRhTDhQb2l0Qi1PXzl2U3R3ZlREZTFwMHZvWjB2ZFFuc0czVDZXdkcxa2Q4MEVYWG5kVjd4UmlVbk5Db0FweFBXUE1pcE4tYkpnWkNYQ2o0Q2NPa1loOTRETnpEdmJ3S1ZNdEJTS2pGMmlsWjh1WTd1TFNpVGtzZ1lHelA0VzZPOGo4eVJiUE4tN2pYMkJ0cUpwTGV2d19xS25EQWVONDZXWEhsMXBBUTlaWmxuNjlISTdlTWpTa0pkUnpOR0M1ZWRJUXpXQjBrdXE5X1lBeHB6SGFPUEFoRTNxVGRwN3YtRnV2eHA5V1lOWkcyTGhCM2l6ZV96eDZjTGRaaEtWYjZVZFdUS1FaY0Q4TVRiZUg2X19UajdEbmJ0WFBBbXk4Qm1STw?oc=5","date":"2026-04-01","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Co","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPcUNUUXNwaHV4WS1Za1FaWE5kOWREbG8yWDU3TzRJQVR1Z0JBOElqbXhUcDlGUXJLWmNWLTJ4VWNMV3lRTmRVN1JfUlJ2Wnp2ODVXZTZ4c2kyNzlxdHJyZXFibnV5TEo1bVZXTTZoNUYwTGVLWVFCVC1jbGVxXy04WjlKLWxjTF82M1pkLU1vdHBRNzlKWkVPOE9NMjF4VTZsM2p5NklVT2JaYUlvdm5oNzQwRkc5Qkw0aVdZTzBTRlQ5QjZyNS1yemFmR09FejZReDh6OG1hMkpFazRLMDZzbTY1WmZpQ01xMV9td3JFSjhmdndIemRBRWpPLXhGbTBNX1NIc29BT1dBa2dDMEdJbHNvZ3g2QWstdFptU2RMX05jYklzTVdEWDVLdFZQYk5UX2lJMkhWNkpJMGxD?oc=5","date":"2026-03-27","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOeGUtRkVrOEMyNGY0T0VQcDQ4SlUyN0cxNTlJa010alNmb1FxRjJNaS1XRy1FOUxjRmlhcDJpbWo4OHl4cWVma2lJRV9iWTh3U1hORzdoNVdFOHRsZ0JmVDlwZk50U1Nwazl2bGlSVER1b05wRm1sY2VmSmVRSDBwdmV3ZW83MWZ1c1k0MjJlWV94UkYwbnlDMjZjWGNJWlFDbDh2by1jNVpEVEVFbUhUaA?oc=5","date":"2025-11-25","type":"deal","source":"Seeking Alpha","summary":"Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout (NASDAQ:BCAX) - Seeking Alpha","headline":"Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout (NASDAQ:BCAX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPTzAtaVkxWjkxWVg4YnVwa2s0MlZya3lHRVZrWTJfU0tJNlJ4SFF2ZHV2Z0NLVXJxVWMwaXZEQTZuOHpaLTgyTEp2NXQ4QVFpS1VSRGpLMVhhT1BfX1dyVmJvb3FaN2ZnVFJiLWM5dVlRVTJGWE1OeXhHYl8zNkNYR3ZyVEoxTkhSd3hmYmJCcDY3SlZCdEpUaC04emFCN0k5WDdzcnU4MTVmX0xGV0ZIZWkyY2RCWXpIb0YtazZjOE9US0d0dnk5SS13?oc=5","date":"2025-10-13","type":"regulatory","source":"TradingView","summary":"Key facts: Merck reports $63.62B revenue; Bicara gains FDA breakthrough - TradingView","headline":"Key facts: Merck reports $63.62B revenue; Bicara gains FDA breakthrough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5CTjZYRzBtRFMycFRTSXVLM0xJRWFhQUZhMTEtQW4zTWtpLS1sZ0VXU0VtTkp5QVlmVlJCdURrU3o2bGFTMkx4TU4tZUVwN0dwcHlKOXhJeDlINUxxMzBxRm05cWM?oc=5","date":"2025-09-02","type":"pipeline","source":"Fierce Pharma","summary":"Claire Mazumdar - Fierce Pharma","headline":"Claire Mazumdar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNMGNya0JjR2JTQWYyRGF2dTlmUy1tcXJETk80R0RLSjBrUW9wZHdJeU5wVUJNbV83eWt2MjE4dUExcWd1OUNZaEpIMUZNa05uaFc5dXpTLWY2c2VpbUg1SnVaWFJjci1ZM2dqSnJ0aURFSm53R3FpQkpKWHI5TVl4SW5UQVB1d2VOOVNFa1dUV3Z4RWN1Znk0ckh4RkhnZXVqM2J4UXBmRlNGcWM?oc=5","date":"2025-06-15","type":"pipeline","source":"MedCity News","summary":"ASCO 2025 Recap: Rise of the Bispecifics, Dueling Degraders, ADCs of Interest & More - MedCity News","headline":"ASCO 2025 Recap: Rise of the Bispecifics, Dueling Degraders, ADCs of Interest & More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOdldSTVlEekdhRXVEczZJb2pKNjJJazhjVFpRMC1iYjFQVTFFclZTY0JXNXlYUTBGdVdpamh1bFc2bHNaczFKQTdxblIxMkdvNUY2SGVnYkpfTXNneU1NTDdLNEdsejVQRzI4d08tNE5jWUxCZ1N2VmNwNFNYaDZQdTNiSmd0ZzVud0ZqYU8wSjRtZmw2MzZwdlYyMTVXM3VwS3c?oc=5","date":"2025-06-01","type":"pipeline","source":"Fierce Biotech","summary":"ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset - Fierce Biotech","headline":"ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ZVU96aXlkM2hxcjFpWlM2czV4TGJ4dVZERmEzQnl3UlhSekdyRDREc1czQ2tBY2FoNEFjdU02YnBmM3Zwd3RObG9kMkNVUXI5YlVR?oc=5","date":"2025-05-22","type":"trial","source":"FirstWord Pharma","summary":"ASCO25: Bicara stumbles on head-and-neck cancer readout - FirstWord Pharma","headline":"ASCO25: Bicara stumbles on head-and-neck cancer readout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBSOFoxd3BSNXFzTUhaeDNFQlR5eFJueEJ1RDktS3BHQkFxWUhBTlFucXJyNzkxWHBLeUFPeVhzOF9fbmhRd2QwM2ZsRmlmS1I0X2w4?oc=5","date":"2025-05-22","type":"pipeline","source":"FirstWord Pharma","summary":"ASCO25 abstract roundup: Roche's Itovebi cuts risk of death; Merus' bispecific impresses in HNSCC, while Bicara's disappoints - FirstWord Pharma","headline":"ASCO25 abstract roundup: Roche's Itovebi cuts risk of death; Merus' bispecific impresses in HNSCC, while Bicara's disapp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQWVc3R0dLaVBtSzdMb1g2eTMtMUFaV3ZtQkxOY1hUUEZhNHlNY3NvY0wyN2FWOUt5UmNVOXBJb2huR1Yyc0xrQUNZMy15S1lDY1A1TXZxSUhwZlV4TFBpZFowSUJ6U1hVR2hPSXh4SkU5cWUwYVFMY0E4ajZ6YTQ1RlhvS2RPY3N4X2diRmxtbDJtODJTQlNtTHY5cXItZEltOTRMTDBBYVppYVlpMXFKbDlKckg?oc=5","date":"2025-04-14","type":"pipeline","source":"Fierce Biotech","summary":"'One of the lucky few': Bicara's CEO on operating in today's market, while hoping for a different one - Fierce Biotech","headline":"'One of the lucky few': Bicara's CEO on operating in today's market, while hoping for a different one","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQeEtaS3VRQ0M3SHpFR2dBQ3MtcnU5X0loajI3UzRfU3pVbDlVY1pxaEtQMDRnSGZZUVkwOHFHNVZqOG40c2FuTXRGTnd3dDdOY0Y4UjRNdDVZREU1OWQtZHg1WDYzUmFTblNEMHZJaUZMYmZ5UEE0QkY2eHhRZEVwU2FUZW9zWTZr?oc=5","date":"2024-09-17","type":"pipeline","source":"Yahoo Finance","summary":"Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance","headline":"Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPZkVUQWxNeGFEMzJfdjFHaWw3RDJIUV9aMTNJZFRQRXhtbXVYUnJ5c0gtWXMtREtQSVpMNGk4VzEtTGRJZUhnbDNyY284YzZvS0lhRlA5NXdyOEQ4Q3RWa2dDRFZrWFZXa1lPYWdEYTVReXJ2cVRxZGdHYV9wN0pQVFBkZHlIYmxOTWp0N0pXUTZQOWlJUkR1UTNuTkhoRFdCWFhuR0JWY0pGZ2ItakgxUFBQcjAwZ0xkMG80YkFZcUlXSEFf?oc=5","date":"2024-09-06","type":"pipeline","source":"renaissancecapital.com","summary":"BCAX IPO News - Oncology biotech Bicara Therapeutics sets terms for $200 million IPO - renaissancecapital.com","headline":"BCAX IPO News - Oncology biotech Bicara Therapeutics sets terms for $200 million IPO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":63600000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-137950000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":96685000,"cashHistory":[],"totalAssets":430994000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}